PET Imaging of MMP Activation in AAA: Clinical Component
A first-in-human evaluation of \[64Cu\]-RYM2 with PET/CT will be performed to: a) assess its safety, biodistribution, and radiation dosimetry in normal volunteers (WU) and; b) in AAA patients undergoing surgery (WU and Yale), evaluate radiotracer pharmacodynamics and correlate PET imaging characteristics (WU) with ex vivo tissue measurements (Yale).
• No history of claustrophobia or other preventing condition that has previously or would interfere with completion of protocol-specified imaging sessions.
• Able to comprehend and willing to follow instructions for the study procedures as called for by the protocol.
• Capable of lying still and supine within the PET/CT scanner for \
⁃ 1 hour and follow instructions for breathing protocol during the CT portion.
• No illicit drug use or other inhaled drug use (including pharmacologic agents, recreational agents, or illicit drugs) within the past year.
• No known history of cardiac, pulmonary, hepatic or renal disease or diabetes
• BMI ≤ 40
• Men or women 40-80 years of age
• Willing and able to provide informed consent
• Medically managed hypertension and hyperlipidemia
• No history of claustrophobia or other preventing condition that has previously or would interfere with completion of protocol-specified imaging sessions
• Able to comprehend and willing to follow instructions for the study procedures as called for by the protocol
• Patients with AAA indicated for surgical repair (5.0 \[female\] - 5.5cm \[male\]), incidentally identified large(r) AAAs (\>5.5 or 6.0 cm), and rapidly expanding AAAs (\> 0.5 cm in 6 months or \> 1 cm in 12 months) per Guidelines of the Society for Vascular Surgery.